MYCR Stock Analysis: Mycronic publ | ST
Specialty Industrial Machinery | ST, Sweden | Market Cap: 67.993m SEK | 12M Return: 56.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 79.0M
EPS Trend: -13.3%
Qual. Beats: 0
Rev. Trend: 96.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mycronic AB (publ) is a Swedish company that develops, manufactures, and sells production equipment for the global electronics industry, operating through four segments: Pattern Generators, PCB Assembly, High-Volume, and Global Technologies. Its products serve a range of end markets, including aerospace, defense, medical, and industrial electronics, and are sold through agents and distributors. The company was originally known as Micronic Mydata AB and was renamed Mycronic AB in June 2014. Mycronic is headquartered in Täby, Sweden, and trades on the Stockholm Stock Exchange under the ticker MYCR.
As a mid-cap company in the Information Technology sector, specifically within Electronic Equipment & Instruments, Mycronic operates in a niche capital-equipment market where customers are typically high-volume electronics manufacturers. Its business model relies on specialized, high-value machinery-such as mask writers for display and semiconductor production-sold globally with supporting service revenue, which is typical for capital-equipment suppliers serving the electronics manufacturing supply chain.
- China display panel capex cycle drives mask writer order growth
- Advanced packaging semiconductor demand lifts Pattern Generator backlog
- PCB Assembly automation solutions expand margins on electronics recovery
| Net Income: 1.74b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -3.03 > 1.0 |
| NWC/Revenue: 46.59% < 20% (prev 39.29%; Δ 7.30% < -1%) |
| CFO/TA 0.17 > 3% & CFO 2.05b > Net Income 1.74b |
| Net Debt (-1.93b) to EBITDA (2.67b): -0.72 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.3m) vs 12m ago -0.18% < -2% |
| Gross Margin: 52.87% > 18% (prev 54.37%; Δ -1.49% > 0.5%) |
| Asset Turnover: 76.39% > 50% (prev 77.76%; Δ -1.37% > 0%) |
| Interest Coverage Ratio: 29.95 > 6 (EBIT TTM 2.31b / Interest Expense TTM 77.0m) |
| A: 0.33 (Total Current Assets 7.32b - Total Current Liabilities 3.29b) / Total Assets 12.3b |
| B: 0.45 (Retained Earnings 5.57b / Total Assets 12.3b) |
| C: 0.20 (EBIT TTM 2.31b / Avg Total Assets 11.3b) |
| D: 1.79 (Book Value of Equity 7.88b / Total Liabilities 4.41b) |
| Altman-Z'' = 6.87 = AAA |
| DSRI: 1.04 (Receivables 2.17b/1.94b, Revenue 8.65b/8.05b) |
| GMI: 1.03 (GM 54.37% / 52.87%) |
| AQI: 0.88 (AQ_t 0.33 / AQ_t-1 0.38) |
| SGI: 1.07 (Revenue 8.65b / 8.05b) |
| TATA: -0.03 (NI 1.74b - CFO 2.05b) / TA 12.3b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at SEK 332.20 with a total of 266,353 shares traded. Over the past week, the price has changed by -1.77%, over one month by +7.02%, over three months by +14.63% and over the past year by +56.21%.
Current recommended Stop Loss: 305.40 (which is 8.1% or 2.3 ATR below the current price).
Mycronic publ has no consensus analysts rating.
P/E Trailing = 39.2559
P/E Forward = 18.0505
P/S = 7.902
P/B = 8.5977
P/EG = 0.4163
Revenue TTM = 8.65b SEK
EBIT TTM = 2.31b SEK
EBITDA TTM = 2.67b SEK
Long Term Debt = 12.0m SEK (from longTermDebt, last fiscal year)
Short Term Debt = 135.0m SEK (from shortTermDebt, last quarter)
Debt = 756.0m SEK (from shortLongTermDebtTotal, last quarter) + Leases 336.0m
Net Debt = -1.93b SEK (calculated: Debt 756.0m - CCE 2.69b)
Enterprise Value = 66.1b SEK (68.0b + Debt 756.0m - CCE 2.69b)
Interest Coverage Ratio = 29.95 (Ebit TTM 2.31b / Interest Expense TTM 77.0m)
EV/FCF = 50.20x (Enterprise Value 66.1b / FCF TTM 1.32b)
FCF Yield = 1.99% (FCF TTM 1.32b / Enterprise Value 66.1b)
FCF Margin = 15.22% (FCF TTM 1.32b / Revenue TTM 8.65b)
Net Margin = 20.07% (Net Income TTM 1.74b / Revenue TTM 8.65b)
Gross Margin = 52.87% ((Revenue TTM 8.65b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 56.46% (prev 60.21%)
Tobins Q-Ratio = 5.37 (Enterprise Value 66.1b / Total Assets 12.3b)
Interest Expense / Debt = 10.19% (Interest Expense 77.0m / Debt 756.0m)
Taxrate = 21.89% (486.0m / 2.22b)
NOPAT = 1.80b (EBIT 2.31b * (1 - 21.89%))
Current Ratio = 2.22 (Total Current Assets 7.32b / Total Current Liabilities 3.29b)
Debt / Equity = 0.10 (Debt 756.0m / totalStockholderEquity, last quarter 7.88b)
Debt / EBITDA = -0.72 (Net Debt -1.93b / EBITDA 2.67b)
Debt / FCF = -1.47 (Net Debt -1.93b / FCF TTM 1.32b)
Total Stockholder Equity = 7.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.33% (Net Income 1.74b / Total Assets 12.3b)
RoE = 23.33% (Net Income TTM 1.74b / Total Stockholder Equity 7.44b)
RoCE = 30.94% (EBIT 2.31b / Capital Employed (Equity 7.44b + L.T.Debt 12.0m))
RoIC = 20.69% (NOPAT 1.80b / Invested Capital 8.71b)
WACC = 10.09% (E(68.0b)/V(68.7b) * Re(10.11%) + D(756.0m)/V(68.7b) * Rd(10.19%) * (1-Tc(0.22)))
Discount Rate = 10.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.00 | Cagr: 36.08%
[DCF] Terminal Value 68.36% ; FCFF base≈1.36b ; Y1≈1.28b ; Y5≈1.19b
[DCF] Fair Price = 84.52 (EV 14.6b - Net Debt -1.93b = Equity 16.5b / Shares 195.3m; r=10.09% [WACC]; 5y FCF grow -7.39% → 2.50% )
EPS Correlation: -13.32 | EPS CAGR: -3.84% | SUE: 0.56 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 18.60% | SUE: 1.94 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.77 | Chg30d=+23.54% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=10.40 | Chg30d=+15.32% | Revisions=+40% | GrowthEPS=+30.1% | GrowthRev=+17.6%
EPS next Year (2027-12-31): EPS=11.20 | Chg30d=+14.40% | Revisions=-25% | GrowthEPS=+7.7% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: +29% (up=3, down=1)